What is the 13F Pro Quality Score for RIGL?

13F Pro ranks RIGEL PHARMACEUTICALS INC (RIGL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RIGL's current score at https://13fpro.ai/research/RIGL (free sign-up required for the full ranking).

Which hedge funds own the most RIGL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RIGL include BlackRock,, ARMISTICE CAPITAL,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RIGL as soon as new 13F filings post.

Where does 13F Pro source RIGL data?

All RIGEL PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. RIGEL PHARMACEUTICALS INC files with the SEC under CIK 1034842. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RIGL in?

RIGEL PHARMACEUTICALS INC (RIGL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are RIGL's largest expenses?

RIGEL PHARMACEUTICALS INC's latest 10-Q reports these as the largest expense items: Selling, general and administrative ($30.7M, +11% YoY); Research and development ($11.7M, +38% YoY); Cost of product sales ($4.6M, +4% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (three months ended March 31, 2026).

How often is RIGL research updated on 13F Pro?

RIGL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RIGEL PHARMACEUTICALS INC(RIGL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1034842 RIGL stock profile & AI dashboard →

13F Pro Quality Score

73.9/100

Rank #174 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

93.5/100

Profitability

93.8/100

Balance Sheet

97.2/100

Earnings Quality

30.0/100

Free Cash Flow

77.9/100

Institutional Flow

58.5/100

Revenue Scale

28.8/100

Dilution Risk

27.9/100

RIGL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for RIGEL PHARMACEUTICALS INC (RIGL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RIGL at 73.9/100 on a 32-signal composite quality model, placing it at rank #174 of 2,879 stocks — the top 10% of the AI-ranked universe. RIGL scores in the top quartile across balance sheet strength (97.2), profitability (93.8), revenue growth (93.5). Areas of concern include revenue scale (28.8) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), RIGEL PHARMACEUTICALS INC reports quarterly revenue of $58.8M, net income of $8.7M, free cash flow of $2.7M. Top institutional holders of RIGL by reported 13-F value include BlackRock,, ARMISTICE CAPITAL,, STATE STREET, based on the most recent SEC filings. RIGL trades on the Nasdaq exchange and files with the SEC under CIK 1034842. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RIGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RIGEL PHARMACEUTICALS INC directly from SEC EDGAR. RIGEL PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 8 and 83 since 2021, currently 73.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about RIGEL PHARMACEUTICALS INC

Quirks, history, and lore behind RIGL — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company · headquartered in South San Francisco · listed on Nasdaq · focused on hematology and immunology.
2
The Numbers
Annual revenue in the tens of millions of dollars — typical for a small biotech leaning heavily on a single approved drug to keep the lights on.
3
The History
Founded in the late 1990s during the biotech boom, it spent years developing drugs that target intracellular signaling pathways before finally winning an FDA approval.
4
The Secret
Its core research platform zeroes in on tyrosine kinase inhibition — the same molecular lever pulled by many blockbuster cancer drugs — but its niche is autoimmune blood disorders.
5
The Lore
Its flagship approved product, fostamatinib, treats a rare condition where the immune system attacks platelets — a disease most people can't spell: immune thrombocytopenia.
6
The Giveaway
Named after a dim but real star in the constellation Orion, this South San Francisco biotech sells Tavalisse — the first-in-class SYK inhibitor for chronic ITP.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving RIGL's Business? Latest 10-Q Breakdown

✓ 22/22 datapoints verified

AI-extracted from RIGEL PHARMACEUTICALS INC's 10-Q filed 2026-05-05 — Q1 2026 (three months ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenues of $58.8M (+10% YoY) driven by 31% growth in TAVALISSE and REZLIDHIA net product sales, partially offset by lower collaboration revenues.

Biggest Revenue Drivers

Total revenue: $58.8M+10% YoY

Product sales, net$54.9M+26% YoY

TAVALISSE sales increased 31% to $37.3M (higher volumes and price), REZLIDHIA increased 31% to $8.0M (higher volumes and price), and GAVRETO increased 7% to $9.6M (higher price per bottle and volumes).

Contract revenues from collaborations$3.9M-60% YoY

Comprised of royalties and delivery of drug supplies from Grifols ($1.8M royalties), Kissei ($1.8M delivery), and Medison ($0.3M); prior year included $3.0M milestone from Kissei related to fostamatinib approval in Korea.

Largest Expense Items

Selling, general and administrative$30.7M+11% YoY

Increased due to $1.6M higher commercial expenses and $1.7M increase in personnel-related costs.

Research and development$11.7M+38% YoY

Increased by $2.6M in clinical trial expenses from timing of IRAK1/4 inhibitor program and $0.7M in other R&D expenses.

Cost of product sales$4.6M+4% YoY

Higher royalties of $0.5M partially offset by $0.3M decrease in product costs from timing of drug supply deliveries.

Margins: Gross margin on product sales improved due to higher volumes and pricing of commercial products, though margin discussion not explicitly provided. Operating income of $11.9M reflects net product sales growth outpacing the modest increase in cost of product sales.

Watch Items from the Filing

Three customers represent 48%, 23%, and 12% of net product sales and collaborations revenue (Q1 2026), with McKesson Corporation increasing from 42% to 48% YoY concentration risk.
Lilly terminated the ocadusertib collaboration agreement effective June 15, 2026, eliminating future milestone and royalty expectations of approximately $657.1M (now reduced from prior estimate).
GAVRETO received boxed warning for serious infections including opportunistic infections in December 2025, with ongoing FDA discussions on confirmatory requirements for thyroid cancer accelerated approval.
On May 5, 2026, company terminated $60M term loan with MidCap and repaid $45M outstanding principal, entering new $40M revolving credit facility (expandable to $60M) with borrowing base dependent on eligible receivables and inventory.
Accumulated deficit of approximately $1.0 billion as of March 31, 2026; company depends on sustained product sales and collaboration revenues to achieve profitability.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$58.8M

Net Income

Q1 2026

$8.7M

Free Cash Flow

Q1 2026

$2.7M

D/E Ratio

Q1 2026

0.11

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+64.1% YoY

$294.3MFY 2025

FY22 $120.2MFY23 $116.9MFY24 $179.3MFY25 $294.3M

Net Income

+1999.1% YoY

$367.0MFY 2025

FY22 $-58.6MFY23 $-25.1MFY24 $17.5MFY25 $367.0M

Operating Income

+418.6% YoY

$125.5MFY 2025

FY22 $-55.5MFY23 $-20.5MFY24 $24.2MFY25 $125.5M

EPS (Diluted)

+1867.7% YoY

$19.48FY 2025

FY22 $-3.44FY23 $-1.44FY24 $0.99FY25 $19.48

Total Assets

+213.2% YoY

$513.6MFY 2025

FY22 $134.3MFY23 $117.2MFY24 $164.0MFY25 $513.6M

Total Debt

-12.5% YoY

$52.5MFY 2025

FY22 $40.0MFY23 $60.0MFY24 $60.0MFY25 $52.5M

Op. Cash Flow

+140.4% YoY

$75.7MFY 2025

FY22 $-73.8MFY23 $-5.7MFY24 $31.5MFY25 $75.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$294.3M +64.1%	$179.3M +53.4%	$116.9M -2.8%	$120.2M -19.4%	$149.2M +37.4%	$108.6M
Net Income	$367.0M +1999.1%	$17.5M +169.7%	$-25.1M +57.2%	$-58.6M -227.0%	$-17.9M +39.8%	$-29.7M
Operating Income	$125.5M +418.6%	$24.2M +218.1%	$-20.5M +63.1%	$-55.5M -344.5%	$-12.5M +56.9%	$-29.0M
EPS (Diluted)	$19.48 +1867.7%	$0.99 +168.7%	$-1.44 +58.1%	$-3.44 -3027.3%	$-0.11 +38.9%	$-0.18
Total Assets	$513.6M +213.2%	$164.0M +39.9%	$117.2M -12.7%	$134.3M -19.8%	$167.3M +51.6%	$110.4M
Total Debt	$52.5M -12.5%	$60.0M +0.0%	$60.0M +50.0%	$40.0M +100.0%	$20.0M +0.0%	$20.0M
Operating Cash Flow	$75.7M +140.4%	$31.5M +648.0%	$-5.7M +92.2%	$-73.8M -1354.8%	$5.9M +111.3%	$-52.2M

AI Insight: RIGL Financial Trends

Equity swung from -$30M to $400M in six quarters as profitability inflected sharply, but revenue has retreated from the Q2 2025 peak.

• Equity turned positive in Q4 2024 at $3M and surged to $400M by Q1 2026, reversing a deeply negative balance sheet.

• Total debt declined from $60M to $45M in Q4 2025–Q1 2026, the first reduction across the observed period.

• Revenue peaked at $102M in Q2 2025 then retreated to $59M in Q1 2026, a 42% decline from peak.

• Operating income expanded from $0M in Q2 2024 to $61M in Q2 2025, but has since pulled back to $12M in Q1 2026.

⚠ Q1 2026 operating cash flow fell sharply to $3M from $22M in Q4 2025 — monitor whether working capital is pressuring cash generation.

⚠ Q4 2025 net income of $268M versus op income of $23M suggests a large non-operating gain; sustainability is unclear.

⚠ Revenue trend post-Q2 2025 peak warrants scrutiny — a durable re-acceleration would be a key bullish inflection.

AI Insight: RIGL Ratio Trends

Rigel's profitability surged from near breakeven in Q2 2024 to sustained double-digit operating margins, but Q1 2026 shows a sequential deceleration worth monitoring.

• Operating margin expanded dramatically from 1.2% in Q2 2024 to a TTM high of 41.6%, signaling a structural shift to profitability.

• D/E ratio collapsed from 18.25 in Q4 2024 to just 0.11 by Q1 2026, reflecting rapid deleveraging and a strengthened balance sheet.

• ROA improved from -3.2% in Q2 2024 to 6.9% in Q1 2026, with a peak of 46.0% in Q3 2025, suggesting asset efficiency gains.

• Q1 2026 operating margin of 20.2% and NPM of 14.7% are the lowest readings since Q1 2025, indicating sequential margin compression.

⚠ ROIC dropped to 10.7% in Q1 2026 from 64.0% in Q3 2025 — a sharp four-quarter deceleration worth tracking for trend confirmation.

⚠ ROE fell to 8.7% in Q1 2026 from 94.9% in Q3 2025; monitor whether this reflects normalization or deteriorating earnings power.

⚠ TTM NPM of 121.5% far exceeds any single-quarter figure, suggesting one-off items in the trailing period that may not recur.

Get alerted when RIGL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RIGEL PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RIGL

BlackRock, Inc.
$47.8M1,768,907 sh
ARMISTICE CAPITAL, LLC
$34.6M1,280,000 sh
STATE STREET CORP
$30.3M1,120,238 sh
VANGUARD CAPITAL MANAGEMENT LLC
$20.7M764,193 sh
MARSHALL WACE, LLP
$16.2M598,378 sh
AMERICAN CENTURY COMPANIES INC
$14.7M544,431 sh
D. E. Shaw & Co., Inc.
$12.1M445,678 sh
GEODE CAPITAL MANAGEMENT, LLC
$11.9M440,626 sh
GOLDMAN SACHS GROUP INC
$11.9M439,101 sh
TWO SIGMA INVESTMENTS, LP
$11.0M405,807 sh

Fund	Value	Shares
BlackRock, Inc.	$47.8M	1,768,907
ARMISTICE CAPITAL, LLC	$34.6M	1,280,000
STATE STREET CORP	$30.3M	1,120,238
VANGUARD CAPITAL MANAGEMENT LLC	$20.7M	764,193
MARSHALL WACE, LLP	$16.2M	598,378
AMERICAN CENTURY COMPANIES INC	$14.7M	544,431
D. E. Shaw & Co., Inc.	$12.1M	445,678
GEODE CAPITAL MANAGEMENT, LLC	$11.9M	440,626
GOLDMAN SACHS GROUP INC	$11.9M	439,101
TWO SIGMA INVESTMENTS, LP	$11.0M	405,807

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RIGL on your watchlist

Track score changes the day RIGEL PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RIGL a good stock to buy?

13F Pro's AI-powered analysis of RIGEL PHARMACEUTICALS INC (RIGL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RIGL are available on the RIGL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RIGL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RIGL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RIGEL PHARMACEUTICALS INC's investment landscape.